The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- 4 Bulletproof Ways to Improve Your Immune System Naturally
- 7 ways to keep mosquitoes away from your baby
- How To Live With Less Sugar In Your Diet – Longevity LIVE – Longevity LIVE
- How to live longer: Bacteria in the gut could boost longevity study – Toys Matrix
- World Lipstick Day: A Beauty Guide To The Perfect Pout – Longevity LIVE – Longevity LIVE
- erythropoietic protoporphyria death from mt 7117 trial
- how long numbness after getting teeth pulled
- dr joseph angel de soto
- can filling numbness last a long time
- TIME MAGAZINE ARTICLE : WHAT DID JESUS SAY ABOUT HEAVEN AND HELL
- Medical genetics wikipedia
- numb chin after tooth exytaction
- how long can numbness last after extraction
- how long does it take for numbness to go away after wisdom tooth extraction
- innie vs outie vulva
|Search Immortality Topics:|
Category Archives: Nano Medicine
Newswise Green manufacturing is becoming an increasingly critical process across industries, propelled by a growing awareness of the negative environmental and health impacts associated with traditional practices. In the biomaterials industry, electrospinning is a universal fabrication method used around the world to produce nano- to microscale fibrous meshes that closely resemble native tissue architecture. The process, however, has traditionally used solvents that not only are environmentally hazardous but also pose a significant barrier to industrial scale-up, clinical translation, and, ultimately, widespread use.
Researchers atColumbia Engineeringreport that they have developed a "green electrospinning" process that addresses many of the challenges to scaling up this fabrication method, from managing the environmental risks of volatile solvent storage and disposal at large volumes to meeting health and safety standards during both fabrication and implementation. The teams newstudy, published June 28, 2021, by Biofabrication, details how they have modernized the nanofiber fabrication of widely utilized biological and synthetic polymers (e.g. poly--hydroxyesters, collagen), polymer blends, and polymer-ceramic composites.
The study also underscores the superiority of green manufacturing. The groups green fibers exhibited exceptional mechanical properties and preserved growth factor bioactivity relative to traditional fiber counterparts, which is essential for drug delivery and tissue engineering applications.
Regenerative medicine is a $156 billion global industry, one that is growing exponentially. The team of researchers, led byHelen H. Lu, Percy K. and Vida L.W. Hudson Professor ofBiomedical Engineering, wanted to address the challenge of establishing scalable green manufacturing practices for biomimetic biomaterials and scaffolds used in regenerative medicine.
We think this is a paradigm shift in biofabrication, and will accelerate the translation of scalable biomaterials and biomimetic scaffolds for tissue engineering and regenerative medicine, said Lu, a leader in research on tissue interfaces, particularly the design of biomaterials and therapeutic strategies for recreating the bodys natural synchrony between tissues. Green electrospinning not only preserves the composition, chemistry, architecture, and biocompatibility of traditionally electrospun fibers, but it also improves their mechanical properties by doubling the ductility of traditional fibers without compromising yield or ultimate tensile strength. Our work provides both a more biocompatible and sustainable solution for scalable nanomaterial fabrication.
The team, which included several BME doctoral students from Lus group, Christopher Mosher PhD20 and Philip Brudnicki, as well as Theanne Schiros, an expert in eco-conscious textile synthesis who is also a research scientist at Columbia MRSEC and assistant professor at FIT, applied sustainability principles to biomaterial production, and developed a green electrospinning process by systematically testing what the FDA considers as biologically benign solvents (Q3C Class 3).
They identified acetic acid as a green solvent that exhibits low ecological impact (Sustainable Minds Life Cycle Assessment) and supports a stable electrospinning jet under routine fabrication conditions. By tuning electrospinning parameters, such as needle-plate distance and flow rate, the researchers were able to ameliorate the fabrication of research and industry-standard biomedical polymers, cutting the detrimental manufacturing impacts of the electrospinning process by three to six times.
Green electrospun materials can be used in a broad range of applications. Lus team is currently working on further innovating these materials for orthopaedic and dental applications, and expanding this eco-conscious fabrication process for scalable production of regenerative materials.
"Biofabrication has been referred to as the fourth industrial revolution' following steam engines, electrical power, and the digital age for automating mass production, noted Mosher, the studys first author. This work is an important step towards developing sustainable practices in the next generation of biomaterials manufacturing, which has become paramount amidst the global climate crisis."
The study is titled Green electrospinning for biomaterials and biofabrication.
Authors are: Christopher Z. Mosher (A), Philip A.P. Brudnickia (A), Zhengxiang Gonga (A), Hannah R. Childs (A), Sang Won Lee (A),Romare M. Antrobus (A)Elisa C. Fang (A), Theanne N. Schiros (B,C)and Helen H. Lu (A,B)
A. Biomaterials and Interface Tissue Engineering Laboratory, Department of Biomedical Engineering, Columbia University
B. Materials Research Science and Engineering Center, Columbia University
C. Science and Mathematics Department, Fashion Institute of Technology
This work was supported by the National Institutes of Health (NIH-NIAMS 1R01-AR07352901A), the New York State Stem Cell ESSC Board (NYSTEM C029551), the DoD CDMRP award (W81XWH-15- 1-0685), and the National Science Foundation Graduate Research Fellowship (DGE-1644869, CZM). The CD analysis system was supported by NIH grant 1S10OD025102-01, and TNS was supported as part of the NSF MRSEC program through Columbia in the Center for Precision Assembly of Superstratic and Superatomic Solids (DMR-1420634).
The authors declare no competing interest.
Columbia Engineering, based in New York City, is one of the top engineering schools in the U.S. and one of the oldest in the nation. Also known as The Fu Foundation School of Engineering and Applied Science, the School expands knowledge and advances technology through the pioneering research of its more than 220 faculty, while educating undergraduate and graduate students in a collaborative environment to become leaders informed by a firm foundation in engineering. The Schools faculty are at the center of the Universitys cross-disciplinary research, contributing to the Data Science Institute, Earth Institute, Zuckerman Mind Brain Behavior Institute, Precision Medicine Initiative, and the Columbia Nano Initiative. Guided by its strategic vision, Columbia Engineering for Humanity, the School aims to translate ideas into innovations that foster a sustainable, healthy, secure, connected, and creative humanity.
Engineer Kathryn A. Whitehead takes us down to the nano level to break down how lipid nanoparticles could revolutionize the way vaccines our delivered to our bodys cells. She speaks at TEDMonterey: The Case for Optimism on August 2, 2021. (Photo: Bret Hartman / TED)
The central topic of Session 3 is, surely, on many of our minds: health. From the technology powering the Pfizer-BioNTech COVID-19 vaccine to new Alzheimers treatment possibilities, these amazing speakers give a glimpse at exciting new frontiers of medicine. Plus, an artist drawing live onstage!
The event: TEDMonterey: Session 3, hosted by TEDs Chris Anderson on Monday, August 2, 2021
Speakers: Uur ahin, zlem Treci, Kathryn Whitehead, Jarrett J. Krosoczka, Ian Kerner, Li-Huei Tsai, Nabiha Saklayen
The talks in brief:
Uur ahin and zlem Treci, cofounders of BioNTech
Big idea: When COVID-19 first reared its many-crowned head in January of 2020, immunologists zlem Treci and Uur ahin saw an opportunity to develop a vaccine at light speed, using revolutionary mRNA technology to turn the bodys own immune system into a COVID-fighting factory.
How? Treci and ahins development of the first approved COVID-19 vaccine impacted the lives of millions if not billions of people worldwide, who were previously defenseless against the deadliest virus to hit humanity in a century. The husband-and-wife team had started their firm BioNTech as a way to bypass the glacial channels of traditional research, and thus were uniquely suited to bring a vaccine to market quickly. Their revolutionary approach used messenger RNA (mRNA) to address the bodys immune system at the cellular level, compiling chemical source code to teach cells how to produce antibodies personalized to each patient. As Treci puts it: mRNA strands are the generals which call all the different special forces and train them on the wanted poster of the attackers. And far from being effective only against COVID-19, mRNA therapy offers the promise of individually adaptable treatments for a variety of cellular disorders, including cancer.
Kathryn A. Whitehead, engineer, teacher, innovator
Big idea: Messenger RNA (or mRNA) is about to change the world forever.
How? After years of research, Kathryn A. Whitehead and her team have finally created the perfect vehicle for delivering life-saving yet delicate mRNA information through vaccines: lipid nanoparticles. She takes us down to the nano level to break down this fatty packaging into its four key ingredients: phospholipids, cholesterol, ionizable lipids and a polymer called PEG. These components make up the ideal shipping materials for delivering life-saving vaccines to our bodys cells. Amazingly, her work is paving the way for mRNA therapies that can treat or cure diseases that have unrelentingly plagued us, including cancer, Type 1 diabetes, muscular dystrophy and cystic fibrosis as well as the flu, malaria, Ebola, Zika and HIV. As she puts it: mRNA therapies are going to usher in a new era of medicine in human health forever, and its all thanks to these fatty little balls that deliver this miracle medicine to exactly where it needs to go.
Jarrett J. Krosoczka delights the crowd with live drawing presentation paired with a poignant autobiographical journey. He speaks at TEDMonterey: The Case for Optimism on August 2, 2021 (Photo: Bret Hartman / TED)
Jarrett J. Krosoczka, author, illustrator
Big idea: Stories keep people alive and help us remember, share and process the human experience.
How? Equipped with sheets of paper and a mug full of markers, Jarrett J. Krosoczka takes us on an autobiographical journey during a live drawing presentation. He begins by drawing his younger self surrounded by his grandfather and the ancestors he was introduced to through family stories. Krosoczka used his sketchbook as a means of escape from the chaos of his upbringing and as a way to connect with his incarcerated mother, who was also an artist. As a teenager, he volunteered at a camp for children with cancer, befriending a four-year-old boy named Eric who had recently been diagnosed with Leukemia. Krosoczkas drawing of Eric is vibrant, depicting the boy with a Power Rangers sword in hand and a huge grin. Krosoczka shares the difficulties of recounting his experience at the camp in his graphic memoir, Sunshine, and how its creation forced him to come face-to-face with unspoken losses. While this can be painful, he explains, stories are an opportunity to understand the human experience, deal with absence and bring loved ones back to life on the page.
Ian Kerner, psychotherapist
Big idea: If youre experiencing a lack of sexual desire, increasing psychological stimulation can help boost feelings of arousal.
How? Failure to launch, or the inability to build and maintain sexual momentum, is a common problem plaguing the couples who work with sex therapist Ian Kerner. His solution? An arousal runway of psychological stimulation. In other words, he suggests getting the mind in on the action before anything physical begins. For couples dealing with shame around sex, he recommends starting with side-to-side experiences like listening to a sexy podcast together or reading literary erotica aloud. Other couples might try face-to-face experiences, such as sharing sexual fantasies to bring some psychological stimuli back into the relationship. After a year spent in a pandemic (and in our pajamas), Kerner reminds us that if were not feeling super sexy, theres nothing wrong with our libidos we just need to try some new strategies to get the sparks flying.
Li-Huei Tsai, professor, neuroscientist
Big idea: A promising approach to Alzheimers and dementia treatment lies in a mind-blowing (or rather, mind-healing) application of gamma wave stimulation.
How? Of the many signals that fire our synapses, the brain relies on gamma frequencies, or waves, to coordinate cellular activity and keep everything in sync. So when these specific brain waves become weaker, it is often an early indication of dementia or Alzheimers. In seeking to understand and treat this degenerative disease, Li-Huei Tsai and her team asked an intriguing question and found promising answers: What if we artificially boosted the brains gamma waves? They started with mice and, through light and sound stimulation carrying the gamma frequency, discovered profound benefits, such as improved memory and less brain decay. But as Tsai says, mice are nice but people are the point. Now theyre testing on humans with an at-home device that emits the same gamma output and the results, so far, are exciting: reduced brain atrophy, improved mental function and increased synchrony. While its early days and theres still work to be done, shes already seeing a lot of evidence that this approach seems safe and that humans tolerate gamma wave stimulation well meaning this non-invasive treatment could prove accessible for those who need it and usher in a better world and brighter future for everyone.
Nabiha Saklayen, biotech entrepreneur
Big idea: The future of regenerative medicine is personalized.
How? What if diseases could be treated with a patients own cells precisely and on demand? This may sound like science fiction, but through personalized, stem-cell-derived therapies, Nabiha Saklayen says this future is closer than we think. How could this work? The answer lies in automation through machine learning. Currently, stem cells are painstakingly difficult (and expensive) to engineer, requiring scientists to manually remove unwanted cells from stem cell cultures. Saklayen describes how we could leverage physics, biology and algorithms to scale up an alternative, affordable approach gathering the perfect culture of your own personal stem cells by utilizing the precision of a computer. Imagining a revolution in personalized pharmaceuticals, forecasts a world where every person could have a personalized bank of these cells to be used as needed.
Researchers from The University of Manchester and Harvard University have collaborated on a pioneering project in bioengineering, producing metal-free, hydrogel electrodes that flex to fit the complex shapes inside the human body.
Replacing rigid metals
Tringides and Mooney, in collaboration with the Nanomedicine Lab in Manchester, identified a mixture of graphene flakes and carbon nanotubes as the best conductive filler, replacing the use of traditional rigid metals.
Cinzia Casiraghi, Professor of Nanoscience from the NGI and Department of Chemistry at Manchester, said: "This work demonstrates that high-quality graphene dispersions - made in water by a simple process based on a molecule that one can buy from any chemical supply - have strong potential in bioelectronics. We are very interested in exploiting our graphene (and other 2D materials) inks in this field."
Kostas Kostarelos, Professor of Nanomedicine and leader of the Nanomedicine Lab, added: "This truly collaborative effort between three institutions is a step forward in the development of softer, more adaptable and electroactive devices, where traditional technologies based on bulk and rigid materials cannot be applied to soft tissues such as the brain."
Source: University of Manchester
Top image source: Wyss Institute at Harvard University
Xu M, Yao C, Zhang W, Gao S, Zou H, Gao J. Int J Nanomedicine. 2021;16:27352749.
The authors have advised the Acknowledgment statement on page 2748 is incorrect. The acknowledgment section should read as follows:
The authors acknowledge the formulation for the docetaxel in Poly(2-oxazoline) micelles previously developed and published by the Kabanov lab with reference to Seo Y, Schulz A, Han Y, et al. Poly (2-oxazoline) block copolymer based formulations of taxanes: effect of copolymer and drug structure, concentration, and environmental factors. Polym Adv Technol. 2015;26(7):837850 (https://doi.org/10.1002/pat.3556).24 The current article reports the authors original research evaluating this polymeric micelle formulation of docetaxel in their own animal models. Dr Jing Gao wishes to acknowledge her time spent as a visiting scholar to the Kabanov lab at UNC-Chapel Hill from 2013-2014. This study was supported by Military Medical Innovation Project (16CXZ032), National Science and Technology Major Projects for Major New Drugs Innovation and Development (No. 2018ZX09J18107-003, 2018ZX0 9721003-005-009) and NSFC projects (No. 81773278, 81702491).
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Global Nanobiotechnologies Markets Report 2021: Comprehensive and Thorough Review of the Current Status of Nanobiotechnology, Research Work in…
DUBLIN, May 21, 2021 /PRNewswire/ -- The "Nanobiotechnologies - Applications, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
Nanobiotechnology, an integration of physical sciences, molecular engineering, biology, chemistry and biotechnology holds considerable promise of advances in pharmaceuticals and healthcare.
The report starts with an introduction to various techniques and materials that are relevant to nanobiotechnology. It includes some of the physical forms of energy such as nanolasers. Some of the technologies are scaling down such as microfluidics to nanofluidic biochips and others are constructions from bottom up. Application in life sciences research, particularly at the cell level sets the stage for the role of nanobiotechnology in healthcare in subsequent chapters.
Some of the earliest applications are in molecular diagnostics. Nanoparticles, particularly quantum dots, are playing important roles. In-vitro diagnostics, does not have any of the safety concerns associated with the fate of nanoparticles introduced into the human body. Numerous nanodevices and nanosystems for sequencing single molecules of DNA are feasible. Various nanodiagnostics that have been reviewed will improve the sensitivity and extend the present limits of molecular diagnostics.
An increasing use of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will be applied at all stages of drug development - from formulations for optimal delivery to diagnostic applications in clinical trials. Many of the assays based on nanobiotechnology will enable high-throughput screening. Some of nanostructures such as fullerenes are themselves, drug candidates, as they allow precise grafting of active chemical groups in three-dimensional orientations.
The most important pharmaceutical applications are in drug delivery. Apart from offering a solution to solubility problems, nanobiotechnology provides and intracellular delivery possibilities. Skin penetration is improved in transdermal drug delivery. A particularly effective application is as nonviral gene therapy vectors. Nanotechnology has the potential to provide controlled release devices with autonomous operation guided by the needs.
Nanomedicine is now within the realm of reality starting with nanodiagnostics and drug delivery facilitated by nanobiotechnology. Miniature devices such as nanorobots could carry out integrated diagnosis and therapy by refined and minimally invasive procedures, nanosurgery, as an alternative to crude surgery. Applications of nanobiotechnology are described according to various therapeutic systems. Nanotechnology will markedly improve the implants and tissue engineering approaches as well.
Of the over 1,000 clinical trials of nanomedicines, approximately 100 are selected and tabulated in major therapeutic areas. Other applications such as for management of biological warfare injuries and poisoning are included. Contribution of nanobiotechnology to nutrition and public health such as the supply of purified water are also included.
There is some concern about the safety of nanoparticles introduced in the human body and released into the environment. Research is underway to address these issues. As yet there are no FDA directives to regulate nanobiotechnology but as products are ready to enter the market, these are expected to be in place.
Future nanobiotechnology markets are calculated on the basis of the background markets in the areas of application and the share of this market by new technologies and state of development at any given year in the future. This is based on a comprehensive and thorough review of the current status of nanobiotechnology, research work in progress and anticipated progress.
There is a definite indication of large growth of the market but it will be uneven and cannot be plotted as a steady growth curve. Marketing estimates are given according to areas of application, technologies and geographical distribution starting with 2020. The largest expansion is expected between the years 2024 and 2030.
Profiles of 252 companies, out of over 500 involved in this area, are included in the last chapter along with their 185 collaborations. The report is supplemented with 51 Tables, 32 figures and 800 references to the literature.
The report contains information on the following:
Key Topics Covered:
Part One: Applications & Markets
3. Nanotechnologies for Basic Research Relevant to Medicine
4. Nanomolecular Diagnostics
6. Role of Nanotechnology in Biological Therapies
7. Nanodevices & Techniques for Clinical Applications
15. Miscellaneous Healthcare Applications of Nanobiotechnology
16. Nanobiotechnology and Personalized Medicine
18. Ethical and Regulatory Aspects of Nanomedicine
19. Research and Future of Nanomedicine
20. Nanobiotechnology Markets
Part Two: Companies
22. Nanobiotech Companies
For more information about this report visit https://www.researchandmarkets.com/r/wk4qzo
Research and Markets Laura Wood, Senior Manager [emailprotected]
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Healthcare Nanotechnology (Nanomedicine) Market will generate massive revenue by 2027 according to forecasts by Report Ocean The Manomet Current -…
Global Healthcare Nanotechnology (Nanomedicine) Market is valued approximately USD 196.47 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 11.9 % over the forecast period 2020-2027. Healthcare Nanotechnology (Nanomedicine) is the product which is nano-formulations of the existing drugs or new drugs or nanomaterials. Nanomedicine helps in improving human health by providing solutions for various life-threatening diseases, like cancer, Parkinsons disease, Alzheimers disease, diabetes, orthopedic diseases, and infections blood, lungs, and cardiovascular system.
For instance: according to the Alzheimers Disease International, there were around 50 million people globally with dementia in 2020, which is expected to double every 20 years. According to the Globocan 2020, the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020. This will increase the demand for effective nanomedicines in the management of the diseases. Further, increasing investments in urgent care, increasing geriatric population and strategic development between hospitals and the manufacturers has led the adoption of Healthcare Nanotechnology (Nanomedicine) across the forecast period. The market has seen positive growth due to investments in new products by research & development.
For Instance: in 2020, Medtronic PLC launched navigated titanium spinal implant, its new Adaptix Interbody System which is with the Titan nanoLOCK Surface Technology. In 2019, Nanobiotix, a clinical stage nanomedicine company had obtained the CE approval for its Hensify (NBTXR3), nanoparticles designed for injection directly into a tumor. However, stringent regulatory issues and high cost of nano-medicines compared to the traditional medicines along with low awareness among consumers in low income countries impedes the growth of the market over the forecast period of 2020-2027. Also, with the increasing prevalence of diseases, technological advancements for early disease diagnosis & preventive intervention the adoption & demand for Healthcare Nanotechnology (Nanomedicine) is likely to increase.
Request for a FREE sample of this market research report@ https://www.reportocean.com/industry-verticals/sample-request?report_id=bw2116
The regional analysis of global Healthcare Nanotechnology (Nanomedicine) market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the growing geriatric population and promptness & affordability of nano-medicines coupled with the well-established healthcare infrastructure along with the huge investments in research & development activities. For instance: according to the http://www.acc.org, in 2018, coronary heart disease was the leading cause of deaths attributable to cardiovascular disease in the United States with 43.8% of total CVD deaths. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rise in research grants, increasing venture capital investors from developing economies of this region and increasing international research collaborations along with the improving healthcare infrastructure would create lucrative growth prospects for the Healthcare Nanotechnology (Nanomedicine) market across Asia-Pacific region.
Major market player included in this report are:Abbott LaboratoriesCombiMatrix CorporationGE HealthcareSigma-Tau Pharmaceuticals, Inc.Johnson & JohnsonMallinckrodt plcMerck & Company, Inc.Nanosphere, Inc.Pfizer, Inc.Celgene Corporation
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:By Diseases:Cardiovascular DiseasesOncological DiseasesNeurological DiseasesOthersBy Application:Drug DeliveryBiomaterialsActive ImplantsOthersBy Region:North AmericaU.S.CanadaEuropeUKGermanyFranceSpainItalyROE
Asia PacificChinaIndiaJapanAustraliaSouth KoreaRoAPACLatin AmericaBrazilMexicoRest of the World
Furthermore, years considered for the study are as follows:
Historical year 2017, 2018Base year 2019Forecast period 2020 to 2027
Send a request to Report Ocean to understand the structure of the complete report @https://www.reportocean.com/industry-verticals/sample-request?report_id=bw2116
Target Audience of the Global Healthcare Nanotechnology (Nanomedicine) Market in Market Study:
Key Consulting Companies & AdvisorsLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Resellers (VARs)Third-party knowledge providersInvestment bankersInvestors